The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Or they are panicking the 42 price didn’t exactly pay off for them, with the presentation coming up and the blackout period over, news flow can certainly arrive. Wouldn’t be surprised over the next couple of weeks this will rapidly go back up as sentiment starts to turn after the initial shock of placing.
You do realise they can administer many cycles over the current treatment of Dox hence why we are seeing results in patients that are still on this chemo approximately a year at a lower dose of AVA6000. It’s the cumulative dose that’s important and number of cycles over the current standard toxic version of the chemo.
Seriously will stick with the case studies and real life result’s, than pay attention to Touk the Sunday scientists analysis. Only takeaway he should be involved with is the pensioners fish and chips on a Friday.
I’m not here to call this stock, Mr truth, I’m here to share my research and have fun waiting for the inevitable FDA approval decision. Traders can do anything they like, to try predict their next gambling fix for all I care.
Sorry wyn the price doesn’t drop from 160 odd to 80 based on a chart when they were presenting to the institutional investors about a placing. It was leaked and sold into. No graph is going to compensate for news like that.
It wasn’t charting that caused the drop it was people in the know. Also on other news I wonder if the presentation Dr Smith has on the 30th has some 2w data available that’s been running for a while now they will have a good idea what’s go on already, especially considering lower more frequent doses seems to be the sweet spot anyways.
Don’t know why anyone would bother charting an aim company tbh. News could arrive at anytime especially considering Avacta research obsessed PI base that can uncover and share things 3-4 days before an RNS arrives (for example launch in Germany is that not RNS worthy?)
Windy on FDA approval in your opinion on the assumption of what oncology drugs are usually valued at not to mention FDA validation of the platform, do we surpass our all time high of 285p? If the answer is yes which let’s be honest it’s hard to argue against that, no matter what you bought in for you will still be making a profit… some people will be making more profits than others however worst case even if you bought at our ATH you would still be making a profit on FDA approval of AVA6000. Hence why I said if you believe in FDA approval you will make money.
All that matters is how much Avacta is worth on FDA approval of AVA6000. Everything else in the meantime is irrelevant, if you believe FDA approval will happen. Main macro points are we are funded and the data is exceptional. All you need to do now is wait for the trials to conclude, which they will in due course and wait for the FDA’s decision. Talking about the past or management etc will have no impact on the trial results and whether the FDA will give the green light.
Hopefully the 2w results will be released by then so we don’t have to listen to the folk that are venting about our management team constantly or they have lost confidence in their investment 🤮🤮. (without all the information) instead of emailing the company. No wonder sentiment is shot reading some posts here you would think the company is a guaranteed failure. Interesting to note is Amazon was pretty much in the same boat. Share price completely decimated sentiment all time low. However the CEO could see the internal metrics and because they didn’t need the share price up to raise cash off the equity markets just ignored it and got on with the day job. Look how that turned out.
Not particularly as not interested and like many others I am holding a significant loss, not hidden that, however it’s being diluted very effectively at these levels. Hindsight is wonderful I think we can all agree we would have preferred to sell out at 160p and buy back in at 45p however that’s not my style, I do the research and happy to wait for the catalyst of FDA approval then see what happens. If the FDA approves this I am still a massive winner without taking any chances. Imagine selling 160 then a LD hit and it surged to 400 ouch you don’t win all the time.
I prefer to keep my average private, however I can assure you I own many shares here and firmly believe the technology will come good and we will get FDA approval in due course. This is a sale for me. Nothing has materially changed since Nov, apart from outrage against the management team. That is a storm in a tea cup.